Merck/Schering-Plough Pharmaceuticals today announced a large scale clinical outcomes trial that will be conducted for VYTORIN(TM) (ezetimibe/simvastatin). The trial known as IMPROVE IT (Improved Reduction of Outcomes: VYTORIN Efficacy International Trial) will evaluate the risk reduction provided by VYTORIN 10/40 mg as compared to Zocor (simvastatin) 40 mg in reducing death and major coronary events in approximately 10,000 patients with acute coronary syndromes (ACS). In clinical trials, VYTORIN has been shown to provide superior LDL cholesterol lowering as compared to Lipitor or Zocor. The intent of the study is to determine whether VYTORIN provides incremental reductions in cardiovascular events in these patients as compared to simvastatin. The primary endpoint of the trial is the composite of death, myocardial infarction (MI), rehospitalization for ACS or revascularization (occurring 30 days or more after the initial event).
